Frizzled class receptor 2 mRNA (FZD2 mRNA)

Frizzled class receptor 2 (FZD2) mRNA encodes a seven-transmembrane domain protein that functions as a primary receptor for Wnt signaling ligands [UniProt: Q14332]. In the context of oncology, FZD2 mRNA is recognized as a significant driver of the epithelial-mesenchymal transition (EMT) and metastasis, particularly in hepatocellular carcinoma (HCC) and other solid tumors [PubMed: 24631834]. Elevated levels of FZD2 mRNA correlate with increased cell migration, invasion, and poor patient prognosis, making it a high-priority target for therapeutic intervention [NCBI Gene: 2535]. Experimental approaches using small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) have demonstrated the ability to knock down FZD2 expression, thereby suppressing oncogenic Wnt signaling and reducing tumor growth in preclinical models [PubMed: 30232254]. Unlike traditional small molecules or antibodies that target the FZD2 protein, mRNA-targeted therapies provide a mechanism to prevent protein synthesis entirely, potentially overcoming limitations related to protein-surface accessibility. However, the therapeutic application of FZD2 mRNA inhibitors faces hurdles such as ensuring targeted delivery to tumor cells and avoiding systemic toxicity related to the essential role of Wnt signaling in bone density and intestinal maintenance [PubMed: 28213343]. As the field of RNA therapeutics advances, FZD2 mRNA remains a compelling target for precision medicine in advanced metastatic cancers.

Other names

Frizzled-2 mRNAFz-2 mRNAhFz2 mRNAFrizzled family receptor 2 mRNAFZD2 transcript

RNA interference (RNAi) and antisense-mediated mRNA degradation leading to reduced protein expression